TEPEZZA
Generic: teprotumumab
- Manufacturer
- Amgen
- NDC
- 75987-130
- RxCUI
- 2274807
- Route
- INTRAVENOUS
- ICD-10 indication
- H06.20
Affordability Check
How much will you actually pay for TEPEZZA?
In 30 seconds, see every legitimate way to afford TEPEZZA — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
About TEPEZZA
What is this medication?
Tepezza is a prescription medication specifically designed to treat Thyroid Eye Disease, which is also known as Graves eye disease. This condition is an autoimmune disorder where the body's immune system mistakenly attacks the tissues behind the eyes, leading to significant inflammation and swelling. As a specialized treatment for this condition, the drug works as a monoclonal antibody that targets the insulin-like growth factor-1 receptor to interrupt the biological processes that cause the symptoms.
The primary clinical objectives of using this medication are to reduce eye bulging, improve double vision, and alleviate the pain and redness associated with the disease. It is administered to patients through an intravenous infusion every three weeks for a total course of eight treatments. By addressing the biological cause of the swelling rather than just the symptoms, this therapy aims to prevent permanent eye damage and improve the overall quality of life for those living with active Thyroid Eye Disease.
Copay & patient assistance
- Patient Copay Amount: As little as $0 out-of-pocket for TEPEZZA and infusion costs for eligible commercially insured patients.
- Maximum Annual Benefit Limit: Not Publicly Available
- Core Eligibility Restrictions: Must be a resident of the United States and commercially insured with financial responsibility for a portion of the drug and/or infusion cost. Not valid for patients whose prescriptions are paid for in part or in full by any government-funded program, including but not limited to Medicare, Medicaid, Medigap, VA, CHAMPUS, DOD, or TRICARE. Residents of Massachusetts or Rhode Island are not eligible for administration (infusion) support.
- RxBIN, PCN, and Group numbers: Not Publicly Available
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for teprotumumab.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup TEPEZZA →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for teprotumumab →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Conditions we've indexed resources for
Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
ENBREL
Also from Amgen · etanercept
Nplate
Also from Amgen · romiplostim
Prolia
Also from Amgen · denosumab
ARANESP
Also from Amgen · darbepoetin alfa
Vectibix
Also from Amgen · panitumumab
XGEVA
Also from Amgen · denosumab
REPATHA
Also from Amgen · Evolocumab
AMJEVITA
Also from Amgen · adalimumab-atto
IVABRADINE
Also from Amgen · Ivabradine
UPLIZNA
Also from Amgen · Inebilizumab
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.